[Transfer] After the government dominates pricing, is it still expected to innovate in drug innovation?

Source: Same freehand

Last Friday, the US House of Representatives passed the Inflation Reduction Act of 2022 with a vote of 220-207. The insulin cost of the elderly is controlled at $ 35/month.

The current president of the United States, Biden, said: "Today, the American people won, and some special interest groups lost." One week ago, the US Senate also passed the bill with a vote of 51-50.

As one of the countries with the highest price of prescription drugs around the world, the U.S. government has been seeking to reduce the price of drugs for decades, but it has never failed to promote major drug pricing reforms. Since 2015, Nancy Pelosi (D-CA), Speaker of the House of Representatives, has been trying to use this legislation through some form of legislation.

It is said that the "medical insurance price negotiation" policy has received more than 80%of the US public support. However, the Pharmaceutical Industry Lobbying Group American Pharmaceutical Research and Management Association (PHRMA) insisted that the bill will end the United States "global leadership in biomedical innovation." PHRMA has spent more than $ 150 million in lobbying against the bill, but failed to succeed. After passing the bill, Stephen Ubl, the head of PHRMA, said in a statement on Friday:

After several months of legislative arguments, we have a bill priced by the party government. This does not make most Americans more affordable, and there will be fewer treatment methods. This is a short commitment, extremely imbalanced bill.

The bill stipulates that the US Medical Insurance and Public Medical Subsidy Service Center (CMS) will negotiate the 10 most of the price of MEDICARE D in 2026. In 2027, there will In part D, there are 20 types B and D drugs in 2029 and after 2029. None of them include drugs with imitation drugs or biological drugs.

The medicines are 50 drugs with the highest total expenditure and 50 total expenditures in the MEDICARE D. Some orphans and low -cost medicines.

For innovative drugs with different listings, the negotiation price is as follows:

● Short -term monopoly drugs and medical care, that is, innovative drugs with a approval period of 12 years and below, the upper limit of the negotiation price is 75%of the average price;

● The monopoly drugs expanded, that is, an innovative medicine between 12 and 16 years, the upper limit of the negotiation price is 65%of the average price;

● Long -term monopoly drugs, that is, innovative drugs with a approval period of more than 16 years, the upper limit of the negotiation price is 40%of the average price.

Bank of America analysts said that Merck's anti -diabetic drugs Januvia and Albervis's blood cancer therapy drug IMBRUVICA will also become one of the many objects of medical insurance negotiations within four years after the bill takes effect.

In addition, Merck's ace drug Keytruda, Eylea, the treatment of Eylea and Anjin's osteoporosis injection drugs, will also become a candidate for price negotiations; the popular immunotherapy Opdivo and Rituxan jointly sold by BMS and Roche are also in place List in it.

Congress also paid a lot of attention to smaller biopharmaceutical companies, and they negotiated to varying degrees on drugs and biological agents.

The pharmaceutical company regards the negotiation part of the reform as price control. If they refuse to negotiate, they will pay a large amount of consumption tax (65%-95%of drug sales).

The US Congress Budget Office (CBO) predicts that from 2020 to 2029, the number of original drugs in the US market will be reduced by 8 types, and in the next few years, a total of more than 30 species will be reduced. However, Bank of America and Switzerland believe that the bill is unlikely to have a substantial impact on the US pharmaceutical industry.

Competition is imminent, but the real impact of the bill on the development of biopharmaceuticals is still unknown.

Disclaimer: This article is the content of Yaozhi.com, and the copyright of the pictures and text belongs to the original author. The purpose of reprinting is to pass more information, which does not represent the viewpoint of this platform. If the content, copyright and other issues are involved in the work, please leave a message on this platform, and we will delete it as soon as possible.

- END -